AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06501183 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CDH17 CAR-T cells
Description: Anti-CDH17 CAR-T cell injection will be administered intravenously after lymphodepleting.
Study NCT04854499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Administered intravenously
Study NCT05325437 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic splenectomy and azygoportal disconnection
Description: The laparoscopic splenectomy and azygoportal disconnection was performed by the same surgical team.
Study NCT06371508 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education based on breast cancer and breast examination
Description: Training for the intervention group will be provided with a 40-45 minute training organized by one of the researchers.
Study NCT06120504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-35T
Description: Given into the vein (IV; intravenously)
Study NCT05533697 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous infusion
Study NCT04991103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DaraVRD
Description: All patients with newly diagnosed multiple myeloma who was enrolled on the study will receive six cycles of combination quadruplet therapy (DaraVRD).~Six 28-day induction cycles of oral lenalidomide (25 mg daily on days 1-21), subcutaneous bortezomib (1.3 mg/m2 on days 1, 8, 15, 22), subcutaneous daratumumab (1800 mg on days 1, 8, 15, 22 of cycles 1-2 and days 1, 15 for cycles 3-6), and oral dexamethasone (40 mg on days 1, 8, 15, and 22).
Study NCT04418232 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Alianza Latina
Description: The main components of Alianza Latina are 1) providing primary care providers with education, training and tools for timely dementia diagnosis and optimal treatment and 2) providing Latino dementia patients with enhanced chronic care through bilingual Health Navigators.
Study NCT04854499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered intravenously
Study NCT04854499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Administered intravenously
Study NCT04854499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Administered intravenously
Study NCT05674552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exogenous ketone ester
Description: 500 mg/kg over 5 min administered by nasogastric tube, followed after 1 hr by repeated hourly doses of 125 mg/kg for 8 hrs.
Study NCT04414514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib 1.5% Cream
Description: Topical Ruxolitinib 1.5% Cream
Study NCT06515184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PharmaNord Bio-Quinone Active CoQ10 Gold 100mg
Description: Each participant receives one softgel three times a day. Arm 1 receives one 100mg softgel and two placebo softgels per day.~Because of the presence of the IND, the dropdown menu does not allow us to choose dietary supplement. The option drug was chosen as the closest permissible option.
Study NCT06515184 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PharmaNord Placebo
Description: Each participant receives one softgel three times a day. Arm 3 receives three placebo softgels per day. Supplement is taken orally in divided doses, with the last softgel not close to bedtime.~Because of the presence of the IND, the dropdown menu does not allow us to choose dietary supplement. The option drug was chosen as the closest permissible option.
Study NCT06515184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PharmaNord Bio-Quinone Active CoQ10 Gold 100mg
Description: Each participant receives one softgel three times a day. Arm 2 receives three 100mg softgels per day. Supplement is taken orally in divided doses, with the last softgel not close to bedtime.~Because of the presence of the IND, the dropdown menu does not allow us to choose dietary supplement. The option drug was chosen as the closest permissible option.
Study NCT04712565 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Astra Tech Implant System Profile EV
Description: dental implant with a sloped neck configuration
Study NCT04712565 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Astra Tech Implant System EV
Description: dental implant with a conventional neck configuration
Study NCT04854499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: Administered intravenously
Study NCT04854499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: Administered intravenously
Study NCT04854499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered intravenously
Study NCT04854499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Administered intravenously
Study NCT04854499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered intravenously
Study NCT04854499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Administered intravenously
Study NCT04854499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Administered intravenously
Study NCT05426681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GlyBURIDE Oral Tablet
Description: Enrolled patients will receive 12 doses of Glyburide starting within 8 hours of spinal cord injury. The dosing regimen involves an initial dose of 1.25mg followed by 11 consecutive doses of 0.625 mg every 6 hours. The total daily dose of Glyburide on Day 1, Day 2, and Day 3 will be 3.125 mg, 2.5 mg, and 2.5 mg respectively.~Intervention: Drug: Glyburide
Study NCT05818007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid
Description: The main function of HA appears to be in tissue healing, by activating and modulating inflammatory responses, stimulating cellular proliferation, migration, and angiogenesis, inducing basal keratinocyte proliferation and re-epithelization by reducing collagen deposition and scarring
Study NCT05818007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium bicarbonate
Description: sodium bicarbonate solution
Study NCT06403150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levetiracetam Injection
Description: Levetiracetam at 60 mg/kg (max dose 4500 mg) will be intravenously administered in 100mL of normal saline at an administration rate of 2-5mg/kg/min or over 10 minutes. After 30 minutes following Levetiracetam needle time reassessment of the patient will be done to determine the outcomes.
Study NCT06403150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosphenytoin Injection
Description: Fosphenytoin at 20 mg/kg (Phenytoin equivalent dose of 15 mg/kg) will be intravenously administered in 100mL of normal saline at an administration rate not exceeding 3mg/kg/min or 150 mg/min. After 30 minutes following the Fosphenytoin needle time reassessment of the patient will be done to determine the outcomes.
Study NCT06674499 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-help rehabilitation model
Description: The intervention measures followed the principles and processes of cognitive-behavioral therapy. Three intervention sessions were conducted over a period of eight weeks. The first session lasted 90 minutes, while the subsequent sessions (in weeks 4 and 8) lasted 45 minutes each and were conducted face-to-face by the therapist.
Study NCT06674499 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional rehabilitation model
Description: The control group, which follows the conventional rehabilitation model, operates under the current standard of cancer treatment and follow-up. In this model, oncology healthcare professionals provide recommendations based on the specific circumstances of the patients. However, the choice of the rehabilitation model is primarily decided by the patients themselves, aligning with current clinical practice.
Study NCT06366022 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The tunnel technique for root coverage with CTG with inner side of the graft
Description: Procedure: The tunnel technique for root coverage with CTG with inner side of the graft
Study NCT06366022 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The tunnel technique for root coverage with CTG with outer side of the graft
Description: The tunnel technique for root coverage with CTG with outer side of the graft
Study NCT05802836 — intervention group
Intervention type: OTHER
Intervention: no interventions
Description: no intervention, only 3 different patients groups
Study NCT05950997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: 100 mg capsules administered by mouth once daily (28-day cycles)
Study NCT05950997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: 100 mg administered intravenously on Day 1 and 900 mg administered intravenously on Day 2, 1000 mg administered intravenously on Day 8 and 15 of cycle 2 and 1000 mg on Day 1 of subsequent cycles for a total of 6 cycles (28-day cycles)
Study NCT04523519 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video directly observed therapy with contingency management
Description: PrEP adherence will be assessed by visual recognition software during video capture and reviewed for confirmation by study staff, ensuring that videos demonstrate study medication dosing by participant. Participants will receive small financial incentives upon confirmation of dosing.
Study NCT04523519 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Integrated Next-Step Counseling
Description: Integrated Next-Step Counseling combines support for behavioral strategies that reduce sexual and injection-related HIV risk and do not involve PrEP, with strategies to support PrEP adherence in brief, client-centered conversations.
Study NCT04523519 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Next-Step Counseling
Description: Integrated Next-Step Counseling combines support for behavioral strategies that reduce sexual and injection-related HIV risk and do not involve PrEP, with strategies to support PrEP adherence in brief, client-centered conversations.
Study NCT06296030 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: POOF ACT program
Description: The goal of this study is to test this culturally tailored intervention (POOF) against classic ACT, to discover if POOF does better at decreasing race-based trauma in African Americans.Guided by the cultural humility framework and social determinants of health model, we examine POOF, a culturally-tailored ACT model for use with anxious African Americans. The POOF approach builds on research on ACT for the general population, an evidence-based intervention, by tailoring the language of ACT while retaining the fidelity of the ACT model. Our hypotheses examine acceptability and attitudes toward treatment, treatment outcomes for psychological symptoms (i.e., anxiety) and an ACT-related outcome (i.e., psychological flexibility), and a possible underlying mechanism of change (i.e., race-based stress).
Study NCT06296030 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Classic ACT program
Description: This protocol is for a classic, non-adapted ACT intervention.
Study NCT06569329 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GentleWave System Root Canal Therapy
Description: This device has 510k market approval for its intended use within this study.
Study NCT06569329 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EdgePro Laser Root Canal Therapy
Description: This device has 510k market approval for its intended use within this study.
Study NCT06569329 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The ProUltra Piezo Ultrasonic with EndoUltra Tips Root Canal Therapy
Description: This device has 510k market approval for its intended use within this study.
Study NCT06570590 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally invasive lapidus procedure with no arthroscopy
Description: The two procedures, with and without arthroscopy, only differ by the method of assessing cartilage removal. Cartilage removal will be assessed arthroscopically in the procedure with arthroscopy. In the procedure without arthroscopy, cartilage removal will be assessed via direct visualization through a mini arthrotomy procedure. After use of the cartilage burr the surgeon will make a small dorsal portal and use this opening to ensure that the cartilage is removed and all debris removed. The incision will be 2 cm long and centered over the dorsal medial aspect of the joint.
Study NCT06570590 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimally invasive lapidus procedure with arthroscopy
Description: After removal of the cartilage with the cartilage burr, a 3.0 arthroscope will be inserted to inspect the joint for all cartilage removal. Any residual cartilage pieces will be removed to ensure complete cartilage debridement from the subchondral bone and fragments removed from the joint.
Study NCT06002685 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attachment and Biobehavioral Catch-Up
Description: The ABC program consists of 10 one-hour home-based sessions delivered by a trained parent coach. Each session includes the mother and her child together and addresses a specific topic. Principal intervention activities include a discussion of basic attachment principles, guided practice of new parenting behaviors, and a review of video clips from previous sessions to help reinforce parenting targets. The parent coach promotes (a) nurturance, especially in response to distress; (b) following the child's lead with delight; and (c) avoiding frightening caregiving behavior. As specified by the ABC protocol, any/all other family members will be invited to observe or participate in each ABC session Each full-time ABC parent coach will serve 8 to 10 families at a time (i.e., complete 8-10 hourly ABC visits per week).
Study NCT06002685 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home-Based Book-of-the-Week
Description: The HBOW program is an active control condition developed by PI Berlin. It consists of 10 English/Spanish developmentally appropriate books hand-delivered weekly to the mothers. During each of the 10 weeks, a trained RA will visit each HBOW mother to drop off the book and to ask briefly about the mother's and child's well-being (using a standard set of questions). Thus, this condition will parallel the intervention condition in duration (number of weeks) and structure, although it will be less intensive in terms of participant contact time per visit.
Study NCT05742178 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation (PN) - More Intensive
Description: The PN intervention will be administered by trained, bilingual CHWs: they will screen participants for cancer screening status and social needs and provide navigational support to cancer screening and social services.
Study NCT05742178 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Materials
Description: Both PN and LI participants will receive tailored educational materials around cancer screening and SDH resources as needed.
Study NCT05742178 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Materials
Description: Both PN and LI participants will receive tailored educational materials around cancer screening and SDH resources as needed.
Study NCT05742178 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Navigation (PN) - Less Intensive
Description: The PN intervention will be administered by trained, bilingual CHWs: they will screen participants for social needs and provide navigational support to social services.
Study NCT06625723 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard postoperative care
Description: This will include medications, rehabilitation schedules, and follow-up visits as normally scheduled.
Study NCT06625723 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard postoperative care
Description: This will include medications, rehabilitation schedules, and follow-up visits as normally scheduled.
Study NCT06625723 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgical Recovery Systems Sleep Aid
Description: Sleep assistive device
Study NCT06571825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: The consolidation therapy involves a regimen of intermediate-dose cytarabine (Ara-C) combined with Ven, specifically Ara-C at 1.0 g/m²/day for 3 days (days 1-3) and Ven at 400 mg/day for 10 to 14 days (days 1-10 to 14), with each cycle lasting 4 to 6 weeks, for a total of 3 consolidation cycles. This is followed by maintenance therapy with azacitidine (AZA) at 50 mg/m²/day for 5 days (days 1-5), with each cycle lasting 4 weeks, for a total of 6 maintenance cycles.
Study NCT06571825 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allogeneic transplant
Description: The consolidation therapy involves allo-HSCT, with the choice of conditioning regimens typically using reduced-intensity conditioning such as the Fludarabine+Busulfan (FluBu) or Fludarabine+Melphalan (FluMel) regimens commonly used by centers, which can also include Ven.~FluBu regimen: Flu 30 mg/m²/day from day -10 to day -5, Bu 3.2 mg/kg/day from day -6 to day -5 or day -7 to day -5, antithymocyte globulin (ATG) (e.g., rabbit ATG at a total dose of 6-7.5 mg/kg, administered from day -4 to day -1), and Ven from day -10 to day -4.~FluMel regimen: Flu 30 mg/m²/day from day -10 to day -5, Mel 50-70 mg/m²/day from day -4 to day -3, ATG and Ven from day -10 to day -4.~12 weeks (±4 weeks) post-HSCT maintenance begins with AZA at 32 mg/m²/day for 5 days (days 1-5), with each lasting 6 weeks, for a total of 6 cycles. Donor lymphocyte infusion is allowed in cases of minimal residual disease (MRD) positivity.
Study NCT06569225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine/Cisplatin/Nab-Paclitaxel and Rilvegostomig
Description: : Patients will receive prior to surgery: 2 cycles of combinational therapy with Gemcitabine (800mg) /Cisplatin (25mg) /Nab-Paclitaxel (100mg) and Rilvegostomig (Q3W). Post-surgical resection, adjuvant therapy will consist of 4 cycles of Gemcitabine (1000mg) /Cisplatin (25mg) and Rilvegostomig (Q3W). Rilvegostomig (Q3W) will be continued for a total of 12 months in the adjuvant phase
Study NCT06190275 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GT201 in combination with PD-1 inhibitors
Description: GT201 in combination with a PD-1 inhibitor for advanced (HNSCC)
Study NCT06014723 — intervention group
Intervention type: PROCEDURE
Intervention: Submaximal balloon angioplasty
Description: The goal of submaximal balloon angioplasty is to use the balloon to improve the stenosis of the criminal artery by more than 20%.
Study NCT05388825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPN171H 2.5mg
Description: TPN171H 2.5mg is recommended to take warm water on an empty stomach (2 hours or more after dinner)
Study NCT06692257 — intervention group
Intervention type: BEHAVIORAL
Intervention: Observation
Description: To perform a comparative analysis of orofacial functions with an emphasis on breathing and chewing patterns in individuals with and without MIH.
Study NCT05388825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPN171H 5mg
Description: TPN171H 5mg is recommended to take warm water on an empty stomach (2 hours or more after dinner)
Study NCT05388825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPN171H 10mg
Description: TPN171H 10mg is recommended to take warm water on an empty stomach (2 hours or more after dinner)
Study NCT05388825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 5mg
Description: Placebo 5mg is recommended to take warm water on an empty stomach (2 hours or more after dinner)
Study NCT05388825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 10mg
Description: Placebo 10mg is recommended to take warm water on an empty stomach (2 hours or more after dinner)
Study NCT06692946 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cooperative Parent-Mediated therapy
Description: Parent-mediated therapy is an intervention where parents are trained to use therapeutic techniques to support their child's development and manage symptoms, often used for conditions like autism spectrum disorder (ASD).
Study NCT06692946 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatement as Usual
Description: Cognitive Behavioral Therapy (CBT) is a structured, short-term psychological treatment that focuses on identifying and changing negative thought patterns and behaviors. It aims to help individuals develop healthier ways of thinking and coping with challenges by addressing both cognitive (thought) and behavioral components.~Parent training is an educational intervention where parents learn strategies and techniques to effectively manage their child's behavior and support their development, often used to address challenges associated with conditions like autism or ADHD.